Lithotripter gains FDA approval; urease inhibitor now available in U.S.
EDAP TMS SA has received FDA clearance to market its newly designed Sonolith I-Sys lithotripter in the United States.
EDAP TMS SA has received FDA clearance to market its newly designed Sonolith I-Sys lithotripter in the United States.
The integrated lithotripter utilizes the company's patented electroconductive technology. EDAP said the device's superior x-ray and ultrasound imaging systems and user-friendly features have contributed to positive treatment outcomes in Europe, where the product was launched in late 2007.
In related news, Mission Pharmacal has announced that acetohydroxamic acid (Lithostat), a urease inhibitor available for urea-splitting urinary infections in association with struvite stones, is now available at U.S. pharmacies nationwide.
Mission said it has successfully contracted with a new supplier of acetohydroxamic acid to re-introduce Lithostat on the market.
In single clinical trials, the product allowed successful antibiotic treatment of urea-splitting infections after surgical removal of struvite stones in patients not cured by 3 months of antibacterial treatment alone. It also reduced the rate of stone growth in patients who were not candidates for surgical removal of stones, according to the company.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
